Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 561 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07257484RecruitingPhase 4
Tirzepatide study for breast cancer survivors with obesity
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
New York, New YorkAges 18 years+ - NCT03671044RecruitingPhase 3
Testing a nano-form of docetaxel for triple-negative breast cancer
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
Columbus, GeorgiaAges 18–65 - NCT04427293RecruitingPhase 1
Testing lenvatinib and pembrolizumab before breast cancer surgery
This early-phase trial tests whether lenvatinib plus pembrolizumab given before surgery can help treat early-stage triple-negative breast cancer. If you qualify, you would receive study medicines before your planned operation to remove the tumor and nearby lymph nodes.
Chicago, IllinoisAges 18 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Birmingham, AlabamaAges 50–70 - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05806060RecruitingPhase 3
Targeted first treatment for a rare TNBC subtype with spread
This Phase 3 trial tests a more precise treatment strategy for a specific rare type of triple-negative breast cancer (TNBC) called the BLIS subtype. It’s for people whose cancer has spread or cannot be fully removed and who have not had chemo or targeted therapy for metastatic TNBC yet.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06355037RecruitingPhase 2
Dasatinib and quercetin for chemo-resistant triple negative breast cancer
This trial tests whether adding dasatinib and quercetin to your treatment can reverse resistance to chemotherapy in triple negative breast cancer that has spread or come back. It aims to help your body respond better to treatment.
ShanghaiAges 18–70 - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT07671885RecruitingPhase 3
Hormone therapy before surgery for premenopausal breast cancer
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
AkitaAges 18 years+ - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT06845319RecruitingPhase 2
Chemo-immunotherapy before surgery for triple-negative breast cancer
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Charleston, South CarolinaAges 18 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT07045311RecruitingPhase 2
JS207 combination therapy for triple-negative breast cancer
This trial tests a new combination treatment for people with advanced triple-negative breast cancer who have not yet received treatment for their advanced disease. It aims to see if the combination can help shrink or control the cancer.
Hefei, AnhuiAges 18–75 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07319195RecruitingEarly Phase 1
Study of a new drug injected into tumors for breast cancer
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07457359RecruitingPhase 2
Toripalimab plus radiation for chemo-resistant triple-negative breast cancer
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
HangzhouAges 18–75 - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT03643861Recruiting
Radiation after lumpectomy for certain early breast cancers
This trial tests a short, highly targeted radiation plan given in five sessions after lumpectomy for early-stage breast cancer. It may help treat the remaining breast area while aiming to limit exposure to healthy tissue.
Birmingham, AlabamaAges 18–99 - NCT04469296Recruiting
Diet changes before surgery for hormone-receptor breast cancer
This trial tests whether changing your diet before your breast surgery can help people with early, hormone-receptor (ER/PR+) breast cancer. It focuses on patients who have not started treatment yet and want to keep surgery as the main treatment.
Montpellier, HeraultAges 18–80
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 561 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.